Elicio Therapeutics To Host June 25 Virtual KOL Event At 2:00 PM ET Highlighting Urgent Need And Phase 2 Progress Of AMP-Powered ELI-002 Vaccine For mKRAS-Driven Pancreatic Cancer

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS ("mKRAS") driven pancreatic ductal adenocarcinoma ("PDAC"), one of the most lethal and underserved solid tumors. To register, click here.

The event will feature insights from leading experts:

• Darrell Irvine, Ph.D. - Department of Immunology & Microbiology, The Scripps Research Institute, Howard Hughes Medical Institute
• Eileen O'Reilly, M.D. - FASCO Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center
  
  
  
   

The event will provide an overview of Elicio's proprietary lymph node-targeting amphiphile ("AMP") platform, which underpins a pipeline of novel immunotherapies designed to generate potent and durable immune responses. The discussion will also focus on Elicio's lead product candidate, ELI-002, an AMP-powered therapeutic vaccine designed to overcome immune evasion. ELI-002 is currently being evaluated in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC, and an event-driven disease-free survival interim analysis of the study is anticipated in Q3 2025.

A live question and answer session will follow the formal presentations.